Literature DB >> 30972817

Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms.

Elisa Rumi1,2, Silvia Zibellini1, Emanuela Boveri3, Chiara Cavalloni2, Roberta Riboni3, Ilaria Carola Casetti2, Michele Ciboddo2, Chiara Trotti2, Cristina Favaron2, Daniela Pietra1, Chiara Candido1, Virginia Valeria Ferretti2, Mario Cazzola1,2, Luca Arcaini1,2.   

Abstract

Entities:  

Year:  2019        PMID： 30972817     DOI： 10.1002/ajh.25489

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  7 in total

1.  Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.

Authors:  Margherita Maffioli; Toni Giorgino; Barbara Mora; Alessandra Iurlo; Elena Elli; Maria Chiara Finazzi; Marianna Caramella; Elisa Rumi; Maria Cristina Carraro; Nicola Polverelli; Mariella D'Adda; Simona Malato; Marianna Rossi; Alfredo Molteni; Alessandro Vismara; Cinzia Sissa; Francesco Spina; Michela Anghilieri; Daniele Cattaneo; Rossella Renso; Marta Bellini; Maria Luisa Pioltelli; Chiara Cavalloni; Daniela Barraco; Raffaella Accetta; Lorenza Bertù; Matteo Giovanni Della Porta; Francesco Passamonti
Journal:  Blood Adv       Date:  2019-11-12

2.  The Journey of Primary Myelofibrosis to Splenic Marginal Zone Lymphoma on the Wheels of Ruxolitinib.

Authors:  Jasmita Dass; Sabina Langer; Jyoti Kotwal; Nitin Gupta
Journal:  Indian J Hematol Blood Transfus       Date:  2020-07-16       Impact factor: 0.900

3.  Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2V617F-myeloproliferative neoplasm.

Authors:  Katsuhiro Fukutsuka; Futoshi Iioka; Fumiyo Maekawa; Miho Nakagawa; Chiyuki Kishimori; Masahiko Hayashida; Shunsuke Tagawa; Takashi Akasaka; Gen Honjo; Hitoshi Ohno
Journal:  J Clin Exp Hematop       Date:  2021-05-14

Review 4.  Standard care and investigational drugs in the treatment of myelofibrosis.

Authors:  Daniela Barraco; Margherita Maffioli; Francesco Passamonti
Journal:  Drugs Context       Date:  2019-09-26

5.  Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies.

Authors:  Rohit Sekhri; Parvis Sadjadian; Tatjana Becker; Vera Kolatzki; Karlo Huenerbein; Raphael Meixner; Hannah Marchi; Rudolf Wallmann; Christiane Fuchs; Martin Griesshammer; Kai Wille
Journal:  Ann Hematol       Date:  2021-08-31       Impact factor: 3.673

Review 6.  Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?

Authors:  Klara Klein; Dagmar Stoiber; Veronika Sexl; Agnieszka Witalisz-Siepracka
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

7.  Coexistence of Myeloid and Lymphoid Neoplasms: A Single-Center Experience.

Authors:  Anthi Bouchla; Thomas Thomopoulos; Sotirios Papageorgiou; Panagiotis Tsirigotis; Efthymia Bazani; Konstantinos Gkirkas; Diamantina Vasilatou; Eirini Glezou; Georgia Stavroulaki; Konstantinos Gkontopoulos; George Dimitriadis; Vasiliki Pappa
Journal:  Adv Hematol       Date:  2019-11-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.